Solventum
SOLV
$78.27
-0.10%
Solventum Corporation is a healthcare company that develops, manufactures, and commercializes solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. It operates as a distinct entity following its spin-off from 3M, positioning itself as a specialized player in medical supplies, dental products, and health information systems. The current investor narrative revolves around the company's performance as a newly independent public entity, with attention focused on its ability to execute its standalone strategy, manage its capital structure post-spin-off, and demonstrate organic growth and margin stability in a competitive healthcare landscape.…
SOLV
Solventum
$78.27
Investment Opinion: Should I buy SOLV Today?
Rating & Thesis: Hold. SOLV presents a high-risk, high-potential-reward situation as a deeply discounted spin-off with unproven standalone execution, making it suitable only for speculative, value-oriented investors with a high risk tolerance. The recent analyst upgrades signal a potential inflection point, but the fundamental picture remains too weak to warrant a Buy rating.
Supporting Evidence: The stock trades at a compellingly low trailing P/E of 8.87x and a forward P/E of 11.19x, a severe discount to its own history. Its Price-to-Sales ratio of 1.66x and EV/EBITDA of 7.04x appear reasonable for the sector. However, this valuation is countered by a -3.71% YoY revenue decline in Q4 2025, negative TTM Free Cash Flow of -$10M, and a 52-week performance that lags the S&P 500 by 16.7%. The recent 18.14% three-month rally suggests some momentum, but it originates from deeply oversold levels.
Risks & Conditions: The two biggest risks are continued revenue stagnation/decline and an inability to generate consistent positive free cash flow. This Hold rating would upgrade to a Buy if SOLV reports two consecutive quarters of positive organic revenue growth and turns TTM FCF positive, signaling successful independence. It would downgrade to a Sell if revenue declines accelerate beyond -5% YoY or if the stock breaks below its 52-week low of $62.38 on worsening fundamentals. Relative to its own compressed history, the stock appears undervalued, but relative to its current growth profile, it may be fairly valued, representing a classic 'value trap' scenario until fundamentals improve.
Sign up to view all
SOLV 12-Month Price Forecast
SOLV is a classic post-spin-off 'show me' story where deep value is counterbalanced by fundamental weakness. The neutral stance reflects the high probability (55%) of a base case where the stock remains range-bound as the company works to prove its independence. The valuation is too cheap to ignore but is justified by the lack of growth and cash flow. The stance would upgrade to bullish on confirmation of sustained revenue growth and positive FCF for two consecutive quarters. It would turn bearish if the stock breaks key support at $62.38 on worsening fundamentals, confirming the downtrend resumption.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solventum's 12-month outlook, with a consensus price target around $101.75 and implied upside of +30.0% versus the current price.
Average Target
$101.75
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$63 - $102
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this is a newly covered stock following its spin-off, which can lead to higher volatility and less efficient price discovery. The consensus sentiment leans bullish, as evidenced by recent institutional rating actions including upgrades from Mizuho (to Outperform) and Keybanc (to Overweight) in early 2026, suggesting growing analyst confidence. The average target price or explicit buy/hold/sell distribution is not provided in the data, preventing a calculation of implied upside or a precise characterization of the consensus. The target range and signal strength cannot be determined from the available data, which includes analyst ratings but not price targets; the recent pattern of upgrades, however, signals a positive shift in analyst sentiment as the company establishes its independent track record, though the limited number of covering analysts means this view is not yet broad-based.
Bulls vs Bears: SOLV Investment Factors
The evidence is currently mixed but leans bearish due to fundamental weakness in revenue and cash flow, despite a compelling valuation discount. The bear case is supported by the concrete data of declining sales and negative TTM free cash flow, which are primary drivers of the stock's significant underperformance. The bull case rests on the deep valuation re-rating and recent positive momentum, suggesting the market may have over-penalized the stock. The single most important tension in the investment debate is whether SOLV's current low valuation (P/E of 8.87x) accurately reflects a permanent state of low growth and execution challenges, or if it represents a classic value trap that will persist until revenue growth and cash flow generation demonstrably improve.
Bullish
- Deeply Discounted Valuation: SOLV trades at a trailing P/E of 8.87x and a forward P/E of 11.19x, a significant discount to its historical multiples of 54.74x and 92.38x from Q4 2025 and Q4 2024, respectively. This severe compression suggests the market has already priced in post-spin-off risks, potentially creating a value opportunity if the company stabilizes.
- Strong Recent Technical Momentum: The stock has gained 18.14% over the past three months and 5.99% over the past month, sharply diverging from its negative 6-month trend and signaling a potential bottoming process. This momentum has occurred while the stock remains 10.6% below its 52-week high of $88.2, indicating room for further recovery.
- Improving Analyst Sentiment: Recent institutional upgrades from Mizuho (to Outperform) and Keybanc (to Overweight) in early 2026 reflect growing confidence in SOLV's standalone execution. While only 5 analysts cover the stock, this positive shift in sentiment is a key catalyst for a newly independent entity.
- Solid Profitability & High ROE: The company maintains a TTM net margin of 18.7% and an exceptionally high Return on Equity of 30.8%, indicating efficient use of shareholder capital. A debt-to-equity ratio of 1.0 shows a balanced capital structure for a new spin-off.
Bearish
- Stagnant and Volatile Revenue: Q4 2025 revenue declined 3.71% YoY to $1.998B, and the multi-quarter trend shows volatility, peaking at $2.161B in Q2 2025. This lack of consistent top-line growth post-spin-off is the core challenge for the investment thesis.
- Extreme Underperformance vs. Market: SOLV has underperformed the S&P 500 by 13.75% over the past six months and by 16.7% over the past year, highlighting significant investor skepticism. This underperformance persists despite a low beta of 0.746, meaning the stock's weakness is largely company-specific.
- Weak and Inconsistent Cash Flow: The company reported negative Free Cash Flow on a TTM basis (-$10M), a critical red flag for financial health. While quarterly operating cash flow was positive $95M, the inconsistency and negative TTM figure raise concerns about capital allocation and investment capacity.
- Post-Spin-Off Execution Risk: As a newly independent entity, SOLV faces significant operational and strategic execution risks without the support of its former parent, 3M. The limited analyst coverage (only 5 analysts) contributes to higher uncertainty and less efficient price discovery.
SOLV Technical Analysis
The stock is in a pronounced downtrend, having declined 4.95% over the past six months and underperforming the S&P 500 by a significant 13.75% over the same period. Currently trading at $78.87, it sits near the middle of its 52-week range, positioned at approximately 62% of the distance from its 52-week low of $62.38 to its high of $88.2, indicating it has recovered from recent lows but remains well off its peak, suggesting lingering investor skepticism. Recent momentum shows signs of a potential short-term recovery, with the stock up 5.99% over the past month and 18.14% over the past three months, sharply diverging from its negative longer-term trend and signaling a possible mean reversion or bottoming process. The stock's beta of 0.746 indicates it is about 25% less volatile than the broader market, which is notable for a healthcare company and suggests its recent price swings have been driven more by idiosyncratic factors than market-wide moves. Key technical levels are clearly defined, with immediate resistance near the 52-week high of $88.2 and strong support at the 52-week low of $62.38; a sustained breakout above the recent recovery highs near $82.46 would be needed to signal a trend reversal, while a breakdown below $62.38 would confirm the resumption of the primary downtrend.
Beta
0.75
0.75x market volatility
Max Drawdown
-27.5%
Largest decline past year
52-Week Range
$62-$88
Price range past year
Annual Return
+0.0%
Cumulative gain past year
| Period | SOLV Return | S&P 500 |
|---|---|---|
| 1m | +2.4% | -1.9% |
| 3m | +23.1% | +13.6% |
| 6m | -0.9% | +9.0% |
| 1y | +0.0% | +20.0% |
| ytd | -0.9% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLV Fundamental Analysis
Revenue growth is currently stagnant and slightly negative, with Q4 2025 revenue of $1.998 billion representing a year-over-year decline of 3.71%. The multi-quarter trend shows volatility, with revenue peaking at $2.161 billion in Q2 2025 before the recent dip, indicating challenges in achieving consistent top-line expansion post-spin-off. The MedSurg segment is the primary revenue driver, but the lack of detailed segment growth data limits a deeper analysis of underlying business line performance. The company is profitable but with low and volatile margins, reporting net income of $63 million in Q4 2025, which translates to a net margin of just 3.15%. Gross margin for the quarter was 49.3%, which is below the trailing twelve-month gross margin of 53.5% indicated in the valuation data, suggesting potential quarterly compression. Profitability has been inconsistent, as evidenced by a much higher net income of $1.266 billion in Q3 2025, largely driven by other income; this volatility complicates the assessment of core operating earnings. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.0, indicating a balanced capital structure for a newly independent company. Financial health is mixed, as the company reported negative free cash flow on a TTM basis (-$10 million), yet generated positive operating cash flow of $95 million in the latest quarter, highlighting variability in cash generation. Return on equity is strong at 30.8%, but this is likely inflated by the relatively low equity base post-spin-off; the current ratio of 1.23 indicates adequate short-term liquidity.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-0.03%
YoY Comparison
Gross Margin
+0.49%
Latest Quarter
Free Cash Flow
$-10000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLV Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 8.87x, while the forward PE is 11.19x, based on estimated EPS of $10.68; the higher forward multiple suggests the market anticipates earnings growth or stabilization in the coming year. Peer comparison is challenging as specific industry average multiples are not provided in the data; however, the stock's Price-to-Sales ratio of 1.66x and EV/EBITDA of 7.04x appear reasonable for a healthcare supplies company, though a definitive premium or discount assessment cannot be quantified without sector benchmarks. Historically, the stock's own valuation has compressed significantly; its current trailing PE of 8.87x is far below its historical PE of 54.74x from Q4 2025 and 92.38x from Q4 2024, indicating the market has drastically re-rated the stock downward, likely pricing in the realities of its standalone performance and growth profile post-spin-off, which may present a value opportunity if fundamentals stabilize.
PE
8.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -11x~92x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: SOLV's primary financial risk is its inconsistent cash generation, evidenced by negative TTM Free Cash Flow of -$10M, which limits strategic flexibility and raises questions about dividend potential or share buybacks. Revenue concentration in the MedSurg segment (the primary driver) and volatile quarterly profitability—net income swung from $1.266B in Q3 2025 to $63M in Q4 2025—create earnings visibility challenges. The company's valuation is heavily dependent on stabilizing its top line; another quarter of revenue decline could further compress its already low multiples.
Market & Competitive Risks: The stock's primary market risk is continued valuation compression if it fails to demonstrate a credible growth path as an independent company. Trading at a forward P/E of 11.19x, the multiple could contract further if the sector rotates away from value plays or if peers with stronger growth profiles attract capital. As a healthcare supplies company, it faces intense competition and pricing pressure, which is reflected in the quarterly gross margin compression from a TTM level of 53.5% to 49.3% in Q4 2025. Its low beta of 0.746 suggests it is less correlated to market swings, meaning its recovery is contingent on idiosyncratic execution, not a rising market tide.
Worst-Case Scenario: The worst-case scenario involves SOLV failing to achieve operational independence, leading to continued revenue declines, sustained negative free cash flow, and a loss of investor confidence as a standalone entity. This could trigger a re-test and break of the 52-week low of $62.38. Given the stock's recent recovery to ~$79, a breakdown could see a decline of approximately -21% to that low. A further de-rating to a P/E of 6-7x, coupled with an earnings miss, could push the stock into the $50s, representing a potential downside of -30% to -35% from current levels.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to grow as a standalone company, evidenced by the recent -3.71% YoY revenue decline. 2) Financial Risk: Inconsistent profitability and negative TTM Free Cash Flow of -$10M, which limits strategic options. 3) Valuation Risk: The stock could remain a 'value trap' with compressed multiples if growth does not materialize, having already underperformed the S&P 500 by 16.7% over the past year. 4) Market Sentiment Risk: With only 5 analysts covering it, the stock suffers from low visibility and high volatility, amplifying price swings on news.
Our 12-month outlook presents three scenarios. The Base Case (55% probability) sees the stock trading between $75 and $85 as the company stabilizes without significant growth. The Bull Case (25% probability) targets $88 to $95 on successful execution and a valuation re-rating. The Bear Case (20% probability) warns of a drop to $58-$65 if fundamentals deteriorate further. The most likely outcome is the Base Case, predicated on the assumption that revenue flattens and cash flow turns marginally positive, keeping the stock range-bound. The average of these scenarios suggests a cautiously neutral near-term outlook.
SOLV appears statistically undervalued based on its own history, trading at a trailing P/E of 8.87x versus historical multiples above 50x. Its Price-to-Sales ratio of 1.66x and EV/EBITDA of 7.04x also seem reasonable for a healthcare supplies company. However, this discount is justified by its current fundamentals: declining revenue and negative free cash flow. The market is pricing in a scenario of low-to-no growth. Therefore, the stock is fairly valued relative to its present operational profile but deeply undervalued if it can return to even modest growth.
SOLV is a high-risk, speculative buy only for investors with a long time horizon and high risk tolerance. The stock trades at a deeply discounted valuation (P/E of 8.87x) due to post-spin-off uncertainty and weak fundamentals, including a -3.71% YoY revenue decline and negative free cash flow. Recent analyst upgrades and a 3-month price rally of +18.14% suggest a potential inflection, but the investment is a bet on successful turnaround execution. For most investors, it is not a good buy until revenue growth and cash flow stability are demonstrated.
SOLV is unsuitable for short-term trading due to its low beta (0.746) and lack of clear near-term catalysts, which may lead to stagnant price action. It is a speculative long-term investment for investors willing to wait 2-3 years for the post-spin-off turnaround thesis to play out. The investment case hinges on operational improvements that will take multiple quarters to materialize. Given the volatility and uncertainty, a minimum holding period of 18-24 months is suggested to allow for execution proof and potential multiple expansion.